ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
NKGen Biotech Inc

NKGen Biotech Inc (NKGN)

1.19
-0.10
(-7.75%)
Closed June 19 4:00PM
1.19
0.00
(0.00%)
After Hours: 7:58PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.19
Bid
1.20
Ask
1.28
Volume
133,308
1.20 Day's Range 1.34
0.7802 52 Week Range 6.70
Market Cap
Previous Close
1.29
Open
1.30
Last Trade
50
@
1.19
Last Trade Time
Financial Volume
$ 164,638
VWAP
1.235
Average Volume (3m)
1,636,953
Shares Outstanding
21,888,976
Dividend Yield
-
PE Ratio
-0.32
Earnings Per Share (EPS)
-3.79
Revenue
-
Net Profit
-82.95M

About NKGen Biotech Inc

NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearh... NKGen Biotech is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing our proprietary SNK (super-activated) platform. Spearheading our industry disrupting technology are our Senior Leadership, Senior Advisors and Management Team. Together they bring a wealth of knowledge and expertise in neurodegeneration and immune-oncology and are passionate and excited about the work we are doing to strengthen the immune system. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
NKGen Biotech Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker NKGN. The last closing price for NKGen Biotech was $1.29. Over the last year, NKGen Biotech shares have traded in a share price range of $ 0.7802 to $ 6.70.

NKGen Biotech currently has 21,888,976 shares outstanding. The market capitalization of NKGen Biotech is $26.27 million. NKGen Biotech has a price to earnings ratio (PE ratio) of -0.32.

NKGN Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.24-16.78321678321.431.521.22282121.29781867CS
4-0.4-25.15723270441.592.191.24000081.64702433CS
12-0.96-44.65116279072.152.190.82116369531.61748287CS
26-2.29-65.80459770113.484.060.780221660991.84125176CS
52-4.79-80.10033444825.986.70.780215649261.89581287CS
156-4.79-80.10033444825.986.70.780215649261.89581287CS
260-4.79-80.10033444825.986.70.780215649261.89581287CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMTLComtech Telecommunications Corporation
$ 4.07
(87.56%)
91.43M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.36M
ASNSActelis Networks Inc
$ 2.11
(83.48%)
51.37M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
LRHCLa Rosa Holdings Corporation
$ 1.78
(71.15%)
52.9M
STISolidion Technology Inc
$ 0.6881
(-64.35%)
16.36M
DMTKDermTech Inc
$ 0.1488
(-55.25%)
10.74M
QMCOQuantum Corporation
$ 0.3752
(-51.90%)
3.14M
ZNTLZentalis Pharmaceuticals Inc
$ 4.135
(-50.72%)
21.58M
AWINAERWINS Technologies Inc
$ 1.74
(-47.90%)
1.05M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.36M
NVDANVIDIA Corporation
$ 135.58
(3.51%)
294.32M
MBIOMustang Bio Inc
$ 0.8517
(13.56%)
291.95M
CRKNCrown Electrokinetics Corporation
$ 0.0548
(-17.10%)
92.39M

NKGN Discussion

View Posts
frans frans 2 days ago
NKGN no news from the last meeting from 6/10 to 6/13
👍️0
frans frans 7 days ago
no news or when news ???
👍️0
frans frans 7 days ago
what is going on here down down ????
👍️0
philaya philaya 2 weeks ago
Snk02 has extra benefits beyond cancer...
More values.
👍️0
frans frans 2 weeks ago
the news is delayed to next week normal it was from 5/31 to june/3
👍️0
philaya philaya 2 weeks ago
Sold some...
Risky control.
👍️0
Volcano Volcano 2 weeks ago
SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen Biotech, will present details on their cryopreserved allogeneic NK cell therapy platform as well as updated Phase 1 data on its use in solid tumors without lymphodepletion at the 6th Annual Allogeneic Cell Therapies Summit to be held in Boston, MA, from June 10-12, 2024.

Presentation Details:

Title: Protecting Patients by Removing Need for Lymphodepletion to Better Preserve Immune Function

Conference Track: Clinical Track

Date and Time: Wednesday, June 12, 2024, 12:00 pm ET

Dr. Song’s presentation will detail the Company’s novel allogeneic blood-derived NK cell therapy (“SNK02”) commercial manufacturing and cryopreservation process, as well provide an update on their initial Phase 1 results using SNK02 to treat patients with advanced refractory solid tumors. Furthermore, Dr. Song will explore the potential benefits of eliminating pre-treatment lymphodepletion in patients undergoing SNK02 therapy, aiming to safeguard immune function and aid in recovery. Avoiding lymphodepletion before administering cancer treatment can provide many benefits including reduced toxicity, preservation of immune function, and potentially enhancing treatment efficacy. The presentation will also include a discussion on an unexpected discovery from the SNK02 Phase 1 trial, hinting at its possible applicability as a treatment for patients beyond cancer.
👍️0
Volcano Volcano 3 weeks ago
Next week
100% pop coming
👍️0
frans frans 3 weeks ago
where is the huge news ??? on Tuesday
👍️0
philaya philaya 3 weeks ago
kep buying...
still low.
👍️0
Muhbruh Muhbruh 3 weeks ago
Took $NKGN for a swing low float bottom bio with a catalyst coming in a few days and no way to dilute right now, great consolidating chart with very low short shares available - 7K and cost to borrow at - 347% , this name also has done big moves recently as well.

$NKGN 01/06/2024 ET - Phase 1 interim data to be presented at ASCO on June 1, 2024
👍️0
philaya philaya 3 weeks ago
after false login screen...
i changed the passwords.
👍️0
Volcano Volcano 3 weeks ago
Any news can pop over $2 again
👍️0
philaya philaya 3 weeks ago
No bears...
Bear traps yes yes
👍️0
Monksdream Monksdream 4 weeks ago
NKGN under $2
👍️0
glenn1919 glenn1919 4 weeks ago
NKGN................................https://stockcharts.com/h-sc/ui?s=NKGN&p=W&b=5&g=0&id=p86431144783
👍️0
Volcano Volcano 4 weeks ago
Huge news on Tuesday PM
👍️0
Volcano Volcano 4 weeks ago
Surprising news!
👍️0
frans frans 4 weeks ago
pls: what is the news for next week ?????
👍️0
Volcano Volcano 4 weeks ago
This will be &100 stock this year if you have patience
This drug heal Alzheimer’s patients indeed
I will hold long term here
👍️0
Volcano Volcano 4 weeks ago
Low volume selling
Big news coming next week
👍️0
philaya philaya 4 weeks ago
buy the dip...
happy buying day.
👍️0
Roadtojourney Roadtojourney 4 weeks ago
This post is not going anywhere, maybe offering imo, i am out, maybe it will go up now. good luck
👍️0
philaya philaya 4 weeks ago
Buying today....
Not small.
👍️0
Triple nickle Triple nickle 4 weeks ago
Patience pays it’ll be four bucks soon enough
👍️0
Roadtojourney Roadtojourney 4 weeks ago
Where are all the traders and the volume??
👍️0
Volcano Volcano 4 weeks ago
SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors.

In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02.

SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion.

SANTA ANA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced an online publication, titled “Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion” at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

This Phase 1 clinical trial is a multi-center, open-label study evaluating the safety and tolerability of SNK02 in participants with pathologically confirmed solid tumors refractory to standard of care therapy. The study drug, SNK02, is a first-in-kind, cryopreserved allogeneic non-genetically modified NK cell product with significant anti-tumor cytotoxicity and over 90% expression of CD16, NKG2D, NKp46, and DNAM-1, that can be consistently produced on a large commercial scale. SNK02 was administered as an intravenous infusion (IV), weekly for eight weeks in patients with advanced solid tumors. The starting dose was 6x109 SNK02 cells. We hypothesized that higher doses of SNK02 (to overcome autodigestion) could be delivered frequently without the need for lymphodepletion and that it might demonstrate activity against solid tumors that have failed multiple prior standard-of-care treatment options. The primary endpoint was safety based on adverse events (AEs), vitals, laboratory tests, and physical exams. Tolerability of SNK02 and maximum tolerated dose were also evaluated.

“Interim data from our Phase 1 clinical study utilizing our second NK cell therapy product, SNK02, demonstrated that the treatment was well-tolerated as a monotherapy in patients with solid tumors refractory to standard of care therapy,” said Paul Y. Song, MD, Chairman and CEO of NKGen. “We are particularly excited because SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens especially with immune checkpoint inhibitors where a robust T-cell response is needed. Using our proprietary allogeneic manufacturing and cryopreservation processes, we are capable of producing hundreds of thousands of potential doses of enhanced NK cell therapies from materials collected from a single donor. Thus, our potential to treat a significant number of cancer patients with SNK02 is remarkably high. We are pleased to see such promising Phase 1 trial results for both of our unique cell therapy candidates: autologous SNK01 for neurodegenerative disease and allogeneic SNK02 for cancer.”

👍️0
Volcano Volcano 4 weeks ago
Looks like huge news coming AH today
Millions of Chinese investors buying here
👍️0
Volcano Volcano 4 weeks ago
SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, which has demonstrated enhanced cytotoxicity and activating receptor expression for the treatment of neurodegenerative diseases and solid tumors, at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) to be held in Nanjing, China, from May 22–24, 2024.

CGCS will showcase exclusive new data in the several areas, including solid tumor treatment, off-the-shelf therapy, innovative cell therapy, AAV gene therapy, affordability of CGT, global cooperation, RNA therapeutics, and CGT commercialization. CGCS 2024 anticipates over 6,000 global attendees, more than 200 exhibitors, greater than 200 world-class speakers from large pharma, innovative biotech, and academia.

NKGen Presentation Details:

Title: Autologous NK Cell Therapy
Session: A: Cell Therapy Focus
Section: A2: Original Innovation in Cell Therapy – Universal and Solid Tumor Treatment
Date and Time: May 23, 2024, at 4:30 PM CST (China Standard Time) UTC/GMT +8
Dr. Song’s presentation will cover a variety of important topics, including industry challenges in manufacturing autologous NK cells at scale, which has been successfully overcome by NKGen’s next-gen CMC manufacturing process in its production of its autologous NK cell therapy product, SNK01. In addition, Dr. Song will discuss the results from SNK01 treatment in combination with either immune checkpoint inhibitors in patients with advanced solid tumors, or, in combination with Erbitux in tyrosine kinase inhibitor-resistant non-small cell lung cancer.

The presentation will also include the scientific rationale and supporting data behind the use of SNK01 in neurodegenerative disease specifically emphasizing the ability of SNK01 to improve levels of amyloid beta, tau, and alpha-synuclein proteins as well as GFAP, NfL, and YKL-40, which are elevated in numerous neurodegenerative diseases including Alzheimer’s, Parkinson’s, Lewy Body Dementia, Frontotemporal Dementia, Multisystem Atrophy, and Progressive Supranuclear Palsy alluding to the potential use of SNK01 to treat these diseases or as a possible prevention in high risk asymptomatic patients with elevated biomarkers.
👍️0
Volcano Volcano 4 weeks ago
The float is locked up now
Easy 100% explosion upon data presentation for cancer tumor on 05/23
👍️0
Volcano Volcano 4 weeks ago
https://stocktwits.com/Gazilla/message/573648389
👍️0
Volcano Volcano 4 weeks ago
I am encouraged by the continued promise of NKGen’s SNK01 NK cell therapy in a difficult to treat disease such as Alzheimer’s,” said Dr. Jesse Carr, MD, Medical Director of Behavioral Research Specialists, LLC in Glendale, CA who is independently overseeing the trial site. “We are seeing remarkable preliminary clinical benefit in all patients without treatment-related adverse events, including apparent improvements in cognitive function, increases in daily living activities and overall quality of life. I look forward to the potential that this novel drug candidate holds as we continue to progress the trial.”
👍️0
Volcano Volcano 4 weeks ago
P1 interim result for cancer tumor treatment will be super positive scheduled to release later this month
$6 price target
👍️0
glenn1919 glenn1919 4 weeks ago
NKGN..........................https://stockcharts.com/h-sc/ui?s=NKGN&p=W&b=5&g=0&id=p86431144783
👍️0
Volcano Volcano 4 weeks ago
Huge news released today

SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events.

Company advances SNK01 into Phase 2 in moderate Alzheimer’s disease; first patient enrolled in Phase 2 expected in Q2 2024.

SANTA ANA, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that its Safety Review Committee has cleared the Company’s cryopreserved autologous, expanded and enhanced SNK01 to progress into Phase 2 clinical development.

NKGen’s initial “proof of concept” Phase 1 study was an open label, 3+3 dose escalation study which demonstrated that even after only four doses (1, 2, or 4 billion cells) given simple IV, that SNK01 was very safe and able to cross the blood brain barrier to reduce amyloid, tau, and alpha-synuclein proteins as well as neuroinflammation in a dose responsive manner. Despite only receiving four doses, 90% of patients (median MMSE score of 14) demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (“ADCOMS”).

Based on this initial pilot experience, NKGen received US FDA clearance for a new Phase 1/2a study in moderate Alzheimer’s disease using its new cryopreserved autologous product at an increased dose of 6 billion cells given every three weeks for a full-year compared to only four total doses in the initial proof-of-concept study. Three patients were enrolled in the Phase I portion to assess the safety of the higher 6 billion cell dose. In this Phase 1 portion of this trial, SNK01 was very well-tolerated, without any drug related adverse effects.

After careful review of the Phase 1 data by a majority independent Safety Review Committee, SNK01 has been cleared by an Internal Review Board (“IRB”) to enter into the Phase 2 portion of the clinical trial. This pivotal stage will assess efficacy and further safety of SNK01 in a larger group of 30 patients with moderate Alzheimer’s disease using a randomized, double-blind design (20 to receive SNK01, 10 to receive placebo). The Phase 2 trial will provide deep insights into the potential benefits and risks of SNK01 in moderate Alzheimer’s Disease, helping clinical researchers to provide validation of the potential therapeutic value of SNK01.

“We are excited to announce another important clinical milestone in our mission to advance SNK01 as the first potential disease modifying treatment of its kind for patients with more advanced Alzheimer’s disease,” said Paul Y. Song, MD, Chairman and CEO of NKGen. “The Phase 2 trial will utilize our cryopreserved SNK01 product given at the highest dose we have ever delivered, and for a full year duration. To date, SNK01 has been found to be well-tolerated with no reported drug-related adverse events. We are also very encouraged with the clinical progress we have made to date in moderate Alzheimer’s disease research and look forward to generating additional significant clinical and biomarker data from our randomized placebo-controlled Phase 2 trial.”

“I am encouraged by the continued promise of NKGen’s SNK01 NK cell therapy in a difficult to treat disease such as Alzheimer’s,” said Dr. Jesse Carr, MD, Medical Director of Behavioral Research Specialists, LLC in Glendale, CA who is independently overseeing the trial site. “We are seeing remarkable preliminary clinical benefit in all patients without treatment-related adverse events, including apparent improvements in cognitive function, increases in daily living activities and overall quality of life. I look forward to the potential that this novel drug candidate holds as we continue to progress the trial.”
👍️0
Volcano Volcano 1 month ago
Think how many Chinese investors will buy this gem upon amazing data release next week
This could be another meme stock exploding 1000%
Exciting P1 interim data release for cancer tumor on May 31 and super interesting P2 interim result for moderate Alzheimer
I guarantee 1000% profit in a month
👍️0
Volcano Volcano 1 month ago
If you check YouTube about NKGN and SNK drug
You will see the super exciting potential of this natural killer cell therapy
They showed amazing results of advanced Alzheimer patience
The company is about to release P1/P2 interim result of moderate Alzheimer patients trial in June
They are infusing higher doses to 20 Alzheimer patience
You never know what will happen upon the amazing data release
👍️0
Volcano Volcano 1 month ago
👍️0
Volcano Volcano 1 month ago
You can make huge profit next week
This undervalued company targeting cancer tumor and Alzheimer and Pakinson
using natural killer cell
many catalysts are coming worth billions dollars soon
👍️0
BurgerKing82 BurgerKing82 1 month ago
Looks intriguing
👍️0
Volcano Volcano 1 month ago
Is it coincidence to have the presentation schedule on 05/23 and 05/30 in a row?
Super news is coming here
👍️0
Volcano Volcano 1 month ago
I expect to see humongous P1 interim result of cancer tumor treatment
This small company is showing super positive result of Cancer treatment and Alzheimer
Why is Market cap under $25mil?
I think super explosion coming next week
👍️0
Volcano Volcano 1 month ago
online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

ePublication Details:

Title: Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion
👍️0
Volcano Volcano 1 month ago
Massive run start next week
Interim result of P1 cancer tumor trial is due this month
👍️0
Volcano Volcano 1 month ago
This news imply huge thing on the way
CEO is not traveling to China only to present the information
He has meeting with big Chinese pharma to make a huge deal
👍️0
Volcano Volcano 1 month ago
SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, which has demonstrated enhanced cytotoxicity and activating receptor expression for the treatment of neurodegenerative diseases and solid tumors, at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) to be held in Nanjing, China, from May 22–24, 2024.

CGCS will showcase exclusive new data in the several areas, including solid tumor treatment, off-the-shelf therapy, innovative cell therapy, AAV gene therapy, affordability of CGT, global cooperation, RNA therapeutics, and CGT commercialization. CGCS 2024 anticipates over 6,000 global attendees, more than 200 exhibitors, greater than 200 world-class speakers from large pharma, innovative biotech, and academia.

NKGen Presentation Details:

Title: Autologous NK Cell Therapy
Session: A: Cell Therapy Focus
Section: A2: Original Innovation in Cell Therapy – Universal and Solid Tumor Treatment
Date and Time: May 23, 2024, at 4:30 PM CST (China Standard Time) UTC/GMT +8
Dr. Song’s presentation will cover a variety of important topics, including industry challenges in manufacturing autologous NK cells at scale, which has been successfully overcome by NKGen’s next-gen CMC manufacturing process in its production of its autologous NK cell therapy product, SNK01. In addition, Dr. Song will discuss the results from SNK01 treatment in combination with either immune checkpoint inhibitors in patients with advanced solid tumors, or, in combination with Erbitux in tyrosine kinase inhibitor-resistant non-small cell lung cancer.

The presentation will also include the scientific rationale and supporting data behind the use of SNK01 in neurodegenerative disease specifically emphasizing the ability of SNK01 to improve levels of amyloid beta, tau, and alpha-synuclein proteins as well as GFAP, NfL, and YKL-40, which are elevated in numerous neurodegenerative diseases including Alzheimer’s, Parkinson’s, Lewy Body Dementia, Frontotemporal Dementia, Multisystem Atrophy, and Progressive Supranuclear Palsy alluding to the potential use of SNK01 to treat these diseases or as a possible prevention in high risk asymptomatic patients with elevated biomarkers.
👍️0
Volcano Volcano 2 months ago
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Mentioned: NKGN
GlobeNewswireApril 24, 2024
SANTA ANA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced an online publication at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31-June 4, 2024.


ePublication Details:

Title: Interim analysis of a phase I study using cryopreserved non-genetically modified allogeneic natural killer cells with enhanced cytotoxicity (SNK02) in patients with advanced solid tumors without lymphodepletion
Authors: Victoria Chua, Sant Chawla, Erlinda Gordon, William Feske, Lucia Hui, Hank Lee, Yoonmi Kang, Juan Mata, Katia Betito, Paul Chang, Paul Song
👍️0
Volcano Volcano 2 months ago
Be patient here
Huge P1 interim data for cancer tumor due this month and humongous P2 interim for moderate Alzheimer due next month
1000% explosion coming
👍️0
frans frans 2 months ago
MM's take it down on trading MM tot MM or short - buyers no interested on FDA 2e half 2024
👍️0
Monksdream Monksdream 2 months ago
NKGN under $2
👍️0

Your Recent History

Delayed Upgrade Clock